UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. ___)

ACCELERATED PHARMA, INC.

(Name of Issuer)

COMMON STOCK, PAR VALUE $0.001

(Title of Class of Securities)

(CUSIP Number)

December 31, 2019

(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the

disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following page(s)

Page 1 of 5 Pages

CUSIP No.

13G

Page 2 of 5 Pages

1.	NAMES OF REPORTING PERSON
	S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
	Alpha Capital Anstalt
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
		(a) ☐
		(b) ☐
3.	SEC USE ONLY

4.	CITIZENSHIP OR PLACE OF ORGANIZATION
	Liechtenstein

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON	5.	SOLE VOTING POWER,– 225,638 Shares (1)

	6.	SHARED VOTING POWER - None

	7.	SOLE DISPOSITIVE POWER – 225,638 Shares (1)

	8.	SHARED DISPOSITIVE POWER – None

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -
	225,638 Shares (1)
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	☐

11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
	5.33%
12.	TYPE OF REPORTING PERSON
	CO

(1) Based on 4,231,421 shares outstanding following a 1.47 for 1 reverse split of 6,220,190 shares outstanding as of June 30, 2019 as described in the Issuer’s registration statement declared effective on November 7, 2019.

CUSIP No.

13G

Page 3 of 5 Pages

ITEM 1

(a) NAME OF ISSUER: Accelerated Pharma, Inc.

ITEM 1

(b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

15W155 81^st Street, Burr Ridge, IL 60527

ITEM 2

(a) NAME OF PERSON FILING: Alpha Capital Anstalt

ITEM 2

(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

Lettstrasse 32, FL-9490 Vaduz, Furstentums, Liechtenstein

ITEM 2

(d) TITLE OF CLASS OF SECURITIES: Common Stock, par value $0.001

ITEM 2

(e) CUSIP NUMBER:

ITEM 3

IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable

ITEM 4

OWNERSHIP

(a) AMOUNT BENEFICIALLY OWNED: 225,638 Shares (1)

(b) PERCENT OF CLASS: 5.33%

(i) SOLE POWER TO VOTE OR DIRECT THE VOTE

225,638 Shares (1)

(ii) SHARED POWER TO VOTE OR DIRECT THE VOTE

0 Shares

(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

225,638 Shares (1)

(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

0 Shares

CUSIP No.

13G

Page 4 of 5 Pages

ITEM 5

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

Not applicable

ITEM 6

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Not applicable

ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not applicable

ITEM 8

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

Not applicable

ITEM 9 NOTICE OF DISSOLUTION OF GROUP

Not applicable

CUSIP No.

13G

Page 5 of 5 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	February 4, 2020
	(Date)

	/s/ Konrad Ackermann
	(Signature)

	Konrad Ackermann, Director
	(Name/Title)

Accelerated Pharma, Inc. SC 13G